STOCK TITAN
  1. Home
  2. Sec-filings
  3. APGE
  4. [Form 4] Apogee Therapeutics, Inc. Insider Trading Activity

Apogee Therapeutics (APGE) CMO sells 26,400 shares in planned open-market trade

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. Chief Medical Officer Carl Dambkowski reported an open-market sale of 26,400 shares of Common Stock on June 22, 2026 at a weighted average price of $132.60 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 22, 2025. After this sale, he directly holds 179,248 shares of Apogee Therapeutics Common Stock.

Positive

  • None.

Negative

  • None.
Insider Dambkowski Carl
Role Chief Medical Officer
Sold 26,400 shs ($3.50M)
Type Security Shares Price Value
Sale Common Stock 26,400 $132.60 $3.50M
Holdings After Transaction: Common Stock — 179,248 shares (Direct, null)
Footnotes (1)
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares sold 26,400 shares Open-market sale on June 22, 2026
Weighted average sale price $132.60 per share Common Stock sale on June 22, 2026
Post-transaction holdings 179,248 shares Direct ownership after June 22, 2026 sale
Sell transactions count 1 transaction Non-derivative sale reported in Form 4
Net buy/sell shares 26,400 net shares sold Net activity from reported Form 4
Rule 10b5-1 plan adoption date September 22, 2025 Plan governing the June 22, 2026 sale
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dambkowski Carl
(Last)(First)(Middle)
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/22/2026S(1)26,400D$132.6(2)179,248D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Apogee Therapeutics (APGE) report for Carl Dambkowski?

Apogee Therapeutics reported that Chief Medical Officer Carl Dambkowski sold 26,400 shares of Common Stock in an open-market transaction. The sale occurred on June 22, 2026 at a weighted average price of $132.60 per share, according to the Form 4 filing.

At what price did Apogee Therapeutics (APGE) CMO sell his shares?

The CMO’s Apogee Therapeutics share sale used a weighted average price of $132.60 per share. The filing notes multiple trades executed between $132.550 and $132.645, and the reporting person can provide detailed breakdowns of shares sold at each individual price.

How many Apogee Therapeutics (APGE) shares does the CMO hold after the sale?

Following the reported sale, Chief Medical Officer Carl Dambkowski directly holds 179,248 shares of Apogee Therapeutics Common Stock. This post-transaction holding figure is disclosed in the Form 4 and reflects his remaining direct ownership after the June 22, 2026 transaction.

Was the Apogee Therapeutics (APGE) insider sale under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025. Such plans allow insiders to pre-schedule trades, helping separate trading decisions from subsequent market-sensitive information.

What does the weighted average price mean in the Apogee Therapeutics (APGE) Form 4?

The reported $132.60 figure is a weighted average sale price across multiple trades. Individual sales occurred between $132.550 and $132.645 per share, and the reporting person undertakes to provide the exact share amounts at each price upon request to interested parties.